Radioimmunolocalization of Tumours by External Scintigraphy after Administration of<sup>131</sup>I Antibody to Human Chorionic Gonadotrophin: Preliminary Communication

Begent, R. H. J.; Searle, F.; Stanway, Glyn; Jewkes, R. F.; Jones, Barbara E.; Vernon, Peter; Bagshawe, K. D.

doi:10.1177/014107688007300905

Cited by 84 publications

(23 citation statements)

References 11 publications

(3 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The details of the antibodies directed against HCG, their purification and radiolabelling have been described previously Begent et al, 1980 Goldenberg et al (1978). Numerical analysis of areas of relative accumulation of 1311 antibody on the subtraction image was performed by the method of Green et al (1984).…”

Section: Antibodiesmentioning

confidence: 99%

“…The sensitivity of this test exceeds that of any present imaging method so that patients with drug resistant choriocarcinoma are seen with rising serum HCG values but no clear indication of the site of active tumour. Antibody imaging, in which tumours are imaged by external scintigraphy after intravenous injection of radiolabelled antibody directed against HCG provides a way of locating these tumours and demonstrating HCG production at the site concerned. Earlier studies of antibody imaging have shown that large deposits of choriocarcinoma can be located and that the sensitivity was sometimes sufficient to make the investigation useful in clinical decision making (Begent et al, 1980;Goldenberg et al, 1980Goldenberg et al, , 1981.…”

mentioning

confidence: 99%

See 1 more Smart Citation

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

Begent¹,

Bagshawe²,

Green³

et al. 1987

Br J Cancer

Self Cite

View full text Add to dashboard Cite

Summary Choriocarcinoma can be imaged by external scintigraphy after intravenous administration of radiolabelled antibody directed against human chorionic gonadotrophin (HCG). The purpose of this study was to investigate whether antibody imaging was sufficiently sensitive and specific to improve the selection of patients for surgical resection of localised deposits of drug resistant or recurrent choriocarcinoma. Eighteen patients with raised serum HCG concentrations in whom the site of tumour was not known were investigated by antibody imaging and conventional imaging methods. When the tumour appeared localised, resection was attempted. Tumour was found at all sites in which both antibody imaging and conventional imaging methods were positive. Antibody imaging gave false positive results in 2 of 18 patients and false negatives in 5. Computerised tomography was false positive in one case and false negative in 2. In these patients, antibody imaging gave true negative and true positive results respectively. Of 8 patients with positive antibody imaging in whom resection was attempted, 5 achieved sustained complete response with up to five years follow up. It is concluded that antibody imaging is useful in selection of patients for surgery in drug resistant or recurrent choriocarcinoma.

show abstract

Section: Antibodiesmentioning

confidence: 99%

mentioning

confidence: 99%

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

Begent¹,

Bagshawe²,

Green³

et al. 1987

Br J Cancer

Self Cite

View full text Add to dashboard Cite

show abstract

“…The use ofradioactive antibodies against certain tumor products for RaID has proved to be a new cancer detection modality (1)(2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). With affinity-purified antibodies to CEA, for example, RaID has been found to be a highly sensitive and specific method, even demonstrating tumor sites that were not revealed by more conventional techniques (3-5, 7).…”

Section: Discussionmentioning

confidence: 99%

“…In cancer, the use of antibodies directed against qualitatively distinct or quantitatively increased substances (tumor "markers") contained in neoplasms permits the visualization oftumor sites by this technology (1,2) and has been applied clinically to detect tumors bearing carcinoembryonic antigen (CEA), a-fetoprotein, and human chorionic gonadotropin (hCG) (3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14).…”

mentioning

confidence: 99%

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Goldenberg¹,

Kim²,

DeLand³

1981

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Radioimmunodetection (RaID) of tumors containing human chorionic gonadotropin (hCG; choriogonadotropin) was evaluated in 25 patients by injecting "3'I-labeled goat antibody IgG against hCG and performing total-body photoscans with a y scintillation camera 24 and 48 hr later. All 10 testicular cancer patients with proven tumor sites had positive RaID results, whereas three cases without known tumor were negative. Four patients with hydatidiform mole and one with degenerative products of conception showed positive RaID results consistent with elevated serum hCG titers. Two putatively false-positive results were obtained in patients with lung or ovarian cancer, whereas a false-negative metastasis to the liver ofa patient with lung cancer and an elevated serum hCG titer was observed. Of 14 tumor sites found by RaID in 10 testicular cancer patients, 4 were revealed by RaID prior to any other detection method used and provided a lead time to definitive diagnosis by other measures of a few days to >1 yr. Although arnumber ofpatients had high serum hCG levels, even exceeding 3 ,ug/ml, the xenogeneic antibody was capable oflocalizing in tumor. No adverse effects were noted in any of the patients studied. Thus, hCG RaID appears to be a safe and effective method of detecting and locating hCG-producing tumors and has been found to disclose occult testicular cancers.Radioimmunodetection (RaID) is the method by which antibodies are used to transport diagnostic amounts ofradioactivity to specific sites of the body for the external scintigraphic demonstration of abnormal sequestration of radioactivity in pathological tissues. In cancer, the use of antibodies directed against qualitatively distinct or quantitatively increased substances (tumor "markers") contained in neoplasms permits the visualization oftumor sites by this technology (1, 2) and has been applied clinically to detect tumors bearing carcinoembryonic antigen (CEA), a-fetoprotein, and human chorionic gonadotropin (hCG) (3-14).The application of RaID appears to be particularly indicated in patients in whom a tumor marker is shown to be increased in the blood, and where the sites of tumor or of marker production are suspected or unknown. We now communicate our experience with RaID using hCG antibodies, emphasizing the use of this approach to disclose occult metastases of testicular cancer.MATERIALS AND METHODS Subjects. RaID was applied to 25 consecutive patients with putative hCG-producing lesions. Thirteen had a history of histologically confirmed testicular cancer and were evaluated for the presence of primary, recurrent, or metastatic disease. In addition, five patients with hCG-secreting hydatidiform moles or uterine choriocarcinoma, patients with diverse ovarian and lung tumors, and a case with degenerative products of conception were included. Tumor sites were confirmed by surgery, biopsy, ultrasonography, radiological studies including computed tomography (CT), arteriography, venacavography, intravenous pyelography, and by other firm clinical evidence...

show abstract

“…Studies in patients were first reported by Goldenberg et al in 1978 using heteroantisera to CEA to image gastrointestinal, ovarian and cervical tumours. This has been extended, using a range of heteroantisera, to include testicular (Goldenberg et al 1981), prostate (Goldenberg et al 1983) and renal malignancies (Belitsky et al 1978) and choriocarcinomas (Begent et al 1980). The development of monoclonal antibody technology has made it possible to obtain virtually unlimited quantities of pure reagents (Kohler & Milstein 1975).…”

Section: Introductionmentioning

confidence: 99%

Is There a Role for Radioimmunolocalization in Diagnosis of Intracranial Malignancies?: Discussion Paper

et al. 1984

View full text Add to dashboard Cite

Radioimmunolocalization of Tumours by External Scintigraphy after Administration of¹³¹I Antibody to Human Chorionic Gonadotrophin: Preliminary Communication

Cited by 84 publications

References 11 publications

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Is There a Role for Radioimmunolocalization in Diagnosis of Intracranial Malignancies?: Discussion Paper

Contact Info

Product

Resources

About

Radioimmunolocalization of Tumours by External Scintigraphy after Administration of131I Antibody to Human Chorionic Gonadotrophin: Preliminary Communication

Cited by 84 publications

References 11 publications

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

The clinical value of imaging with antibody to human chorionic gonadotrophin in the detection of residual choriocarcinoma

Human chorionic gonadotropin radioantibodies in the radioimmunodetection of cancer and for disclosure of occult metastases.

Is There a Role for Radioimmunolocalization in Diagnosis of Intracranial Malignancies?: Discussion Paper

Contact Info

Product

Resources

About

Radioimmunolocalization of Tumours by External Scintigraphy after Administration of¹³¹I Antibody to Human Chorionic Gonadotrophin: Preliminary Communication